293 related articles for article (PubMed ID: 33580980)
1. Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
Venugopal S; Maiti A; DiNardo CD; Loghavi S; Daver NG; Kadia TM; Rausch CR; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Ravandi F; Kantarjian HM; Konopleva MY
Am J Hematol; 2021 May; 96(5):E154-E157. PubMed ID: 33580980
[No Abstract] [Full Text] [Related]
2. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Aldoss I; Yang D; Pillai R; Sanchez JF; Mei M; Aribi A; Ali H; Sandhu K; Al Malki MM; Salhotra A; Khaled S; Sun W; O'Donnell M; Snyder D; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
Am J Hematol; 2019 Oct; 94(10):E253-E255. PubMed ID: 31259427
[No Abstract] [Full Text] [Related]
3. The feasibility of venetoclax and decitabine in therapy-related acute myeloid leukemia with concurrent advanced non-hematological malignancies.
Otoukesh S; Salhotra A; Marcucci G; Forman SJ; Pullarkat V; Aldoss I
Leuk Res; 2019 Sep; 84():106196. PubMed ID: 31377457
[No Abstract] [Full Text] [Related]
4. Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
Andreani G; Dragani M; Serra A; Nicoli P; De Gobbi M; Cilloni D
Am J Hematol; 2019 Feb; 94(2):E48-E50. PubMed ID: 30431666
[No Abstract] [Full Text] [Related]
5. Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia.
Arslan S; Zhang J; Dhakal P; Moran J; Naidoo N; Lombardi J; Pullarkat V; Stein AS; Marcucci G; Yaghmour G; Bhatt VR; Fathi AT; Aldoss I
Am J Hematol; 2021 Mar; 96(3):E59-E63. PubMed ID: 33227142
[No Abstract] [Full Text] [Related]
6. Hypomethylating agents and venetoclax in acute myeloid leukemia.
DiNardo CD
Clin Adv Hematol Oncol; 2021 Feb; 19(2):82-83. PubMed ID: 33596188
[No Abstract] [Full Text] [Related]
7. Venetoclax with decitabine or azacitidine for AML.
Das M
Lancet Oncol; 2018 Dec; 19(12):e672. PubMed ID: 30392809
[No Abstract] [Full Text] [Related]
8. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Aldoss I; Yang D; Aribi A; Ali H; Sandhu K; Al Malki MM; Mei M; Salhotra A; Khaled S; Nakamura R; Snyder D; O'Donnell M; Stein AS; Forman SJ; Marcucci G; Pullarkat V
Haematologica; 2018 Sep; 103(9):e404-e407. PubMed ID: 29545346
[No Abstract] [Full Text] [Related]
10. Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
Salhotra A; Aribi A; Ngo D; Zhang J; Sandhu K; Al-Malki M; Ali H; Koller P; Arslan S; Budde E; Khaled S; Dadwal S; Snyder DS; Artz A; Forman S; Nakamura R; Stein A; Marcucci G; Aldoss I; Pullarkat V
Am J Hematol; 2021 Jun; 96(6):E196-E200. PubMed ID: 33719090
[No Abstract] [Full Text] [Related]
11. Updates on DNA methylation modifiers in acute myeloid leukemia.
Contieri B; Duarte BKL; Lazarini M
Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
[TBL] [Abstract][Full Text] [Related]
12. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Maiti A; Qiao W; Sasaki K; Ravandi F; Kadia TM; Jabbour EJ; Daver NG; Borthakur G; Garcia-Manero G; Pierce SA; Montalbano KS; Pemmaraju N; Naqvi K; Ohanian M; Short NJ; Alvarado Y; Takahashi K; Yilmaz M; Jain N; Kornblau SM; Andreeff M; Bose P; Ferrajoli A; Issa GC; Masarova L; Thompson PA; Rausch CR; Ning J; Kantarjian HM; DiNardo CD; Konopleva MY
Am J Hematol; 2021 Mar; 96(3):282-291. PubMed ID: 33264443
[TBL] [Abstract][Full Text] [Related]
13. RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia.
Chow S; Tang K; Al-Abri M; Hall V; Tremblay-Lemay R; Rashedi I; Tsui H; Chan SM
Leuk Res; 2021 Dec; 111():106735. PubMed ID: 34735933
[No Abstract] [Full Text] [Related]
14. Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy.
Begna KH; Gangat N; Al-Kali A; Litzow MR; Hogan WJ; Patnaik MM; Pardanani A; Hook CC; Wolanskyj AP; Elliott MA; Hanson CA; Ketterling RP; Tefferi A
Am J Hematol; 2021 Apr; 96(4):E108-E111. PubMed ID: 33527451
[No Abstract] [Full Text] [Related]
15. Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia.
Aldoss I; Zhang J; Pillai R; Shouse G; Sanchez JF; Mei M; Nakamura R; Stein AS; Forman SJ; Marcucci G; Pullarkat V
Br J Haematol; 2019 Oct; 187(2):e45-e48. PubMed ID: 31441045
[No Abstract] [Full Text] [Related]
16. Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax.
Diao S; Nichols ED; DiNardo C; Konopleva M; Ning J; Qiao W; Maiti A; DiPippo AJ
Am J Hematol; 2021 Mar; 96(3):E65-E68. PubMed ID: 33259075
[No Abstract] [Full Text] [Related]
17. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
18. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Schuler E; Wagner-Drouet EM; Ajib S; Bug G; Crysandt M; Dressler S; Hausmann A; Heidenreich D; Hirschbühl K; Hoepting M; Jost E; Kaivers J; Klein S; Koldehoff M; Kordelas L; Kriege O; Müller LP; Rautenberg C; Schaffrath J; Schmid C; Wolff D; Haas R; Bornhäuser M; Schroeder T; Kobbe G;
Ann Hematol; 2021 Apr; 100(4):959-968. PubMed ID: 33191481
[TBL] [Abstract][Full Text] [Related]
19. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax in combination with low dose Cytarabine and Actinomycin D for primary refractory acute myeloid leukemia patients failing intensive chemotherapy.
Daraskevicius J; Everatt V; Vaitekenaite V; Ringeleviciute U; Maneikis K; Zucenka A
Leuk Res; 2021 Dec; 111():106692. PubMed ID: 34438121
[No Abstract] [Full Text] [Related]
[Next] [New Search]